Showing results (61-70 of 74) with videos related to
Sort By:
Pageof 8
Dermatology and Therapy|February 5, 2025
Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 MonthsDiamant Thaçi, Mamitaro Ohtsuki, Julia-Tatjana Maul, et al.Dermatology and Therapy|June 27, 2024
Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL StudyBernhard Korge, Olivier Vanhooteghem, Charles W Lynde, et al.Dermatology and Therapy|September 12, 2021
Practical Management of Patients with Atopic Dermatitis on DupilumabKim A Papp, Chih-Ho Hong, M Perla Lansang, et al.American Journal of Clinical Dermatology|February 22, 2023
Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical TrialsJonathan I Silverberg, Charles W Lynde, Katrina Abuabara, et al.Journal of Cutaneous Medicine and Surgery|May 22, 2016
Canadian Clinical Practice Guidelines for RosaceaYuka Asai, Jerry Tan, Akerke Baibergenova, et al.JAAD International|February 3, 2025
Optimizing the management of psoriasis in patients with skin of color: A Canadian Delphi consensusGeeta Yadav, Yvette Miller-Monthrope, Jaggi Rao, et al.Dermatology and Therapy|April 21, 2022
Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert PanelKim A Papp, Jennifer Beecker, Curtis Cooper, et al.Dermatology and Therapy|March 17, 2023
Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert PanelKim A Papp, Barbara Melosky, Sandeep Sehdev, et al.Journal of the American Academy of Dermatology|August 20, 2021
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trialAndrew Blauvelt, Jonathan I Silverberg, Charles W Lynde, et al.NEJM Evidence|November 5, 2025
Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact SitesMelinda Gooderham, Edward Lain, Robert Bissonnette, et al.Pageof 8